Related Experiment Video
Updated: Dec 18, 2025
08:23
Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions
Published on: September 25, 2018
13.8K
One-Step Duplex Droplet Digital PCR for WT1 Overexpression
Laurent Dewispelaere1, Leonore Bleret1, Tom Van Acker1
1Department of Molecular Hemato-Oncology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), The Free University of Brussels, Brussels, Belgium.
The Journal of Molecular Diagnostics : JMD
|June 17, 2020
Summary
A new droplet digital assay accurately detects WT1 gene overexpression in acute myeloid leukemia (AML) patients. This sensitive method aids minimal residual disease monitoring, aligning with established European LeukemiaNet protocols.
Area of Science:
- Hematology
- Molecular Diagnostics
- Oncology
Background:
- Improving acute hematology malignancy treatments necessitates sensitive minimal residual disease (MRD) assessment tools.
- Wilms Tumor 1 (WT1) expression monitoring via real-time quantitative PCR is a standard for MRD evaluation in acute myeloid leukemia (AML).
- The European LeukemiaNet (ELN) optimized WT1 monitoring into a standardized protocol with defined clinical endpoints since 2009.
Purpose of the Study:
- To develop a novel, highly sensitive assay for detecting WT1 overexpression.
- To create a one-step duplex assay combining WT1 and ABL1 detection.
- To provide a reliable tool for MRD assessment in AML patients.
Main Methods:
- Development of a one-step duplex droplet digital assay.
- Utilizing droplet digital PCR (ddPCR) technology for high precision and sensitivity.
- Quantification of WT1 expression levels relative to ABL1 as an internal control.
Main Results:
- The novel assay demonstrates high precision and linearity, even at low WT1 template concentrations.
- The assay accurately detects WT1 overexpression.
- Results show strong correlation with the standardized WT1 monitoring method.
Conclusions:
- The developed WT1/ABL1 droplet digital assay is a sensitive and accurate tool for MRD assessment in AML.
- This assay maintains the framework for analyzing results within the context of AML patient data.
- It builds upon the established ELN efforts for WT1 monitoring in leukemia.
